Grifols, S.A. logo
Grifols, S.A. GRFS
$ 7.62 -1.17%

Annual report 2024
added 03-14-2026

report update icon

Grifols, S.A. Net Income 2011-2026 | GRFS

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income Grifols, S.A.

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - 265 M 619 M 986 M 857 M 730 M 881 M 849 M 712 M 653 M 521 M 110 M

All numbers in EUR currency

Indicator range from annual reports

Maximum Minimum Average
986 M 110 M 653 M

References

  1. Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Biotechnology industry

Issuer Net Income Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
-514 M - 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
-83.7 M - 1052.0 % $ 415 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
-8.37 M - 5.93 % $ 314 M canadaCanada
Akero Therapeutics Akero Therapeutics
AKRO
-252 M - - $ 3.67 B usaUSA
Akouos Akouos
AKUS
-86.7 M - 0.23 % $ 488 M usaUSA
I-Mab I-Mab
IMAB
-1.47 B - - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
603 M - - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
67.3 M - 2.54 % $ 160 B franceFrance
Albireo Pharma Albireo Pharma
ALBO
-34 M - -0.23 % $ 916 M usaUSA
Biophytis SA Biophytis SA
BPTS
-31.2 M - -13.47 % $ 169 M franceFrance
Aileron Therapeutics Aileron Therapeutics
ALRN
-62.9 M - 10.36 % $ 9.8 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-5.46 M - -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
-8.09 M - -1.52 % $ 24.7 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
-168 M $ 2.82 1.44 % $ 283 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-18.4 M - - $ 26.5 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
-19.2 M - -10.17 % $ 12.2 K usaUSA
Aptinyx Aptinyx
APTX
-64.8 M - -39.0 % $ 4.57 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
-253 M - -24.86 % $ 820 K usaUSA
Esperion Therapeutics Esperion Therapeutics
ESPR
-22.7 M $ 2.85 3.26 % $ 592 M usaUSA
Acasti Pharma Acasti Pharma
ACST
-9.57 M - 4.01 % $ 150 M canadaCanada
Equillium Equillium
EQ
-22.4 M $ 2.06 - $ 118 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
72.9 M - - - russiaRussia
Adverum Biotechnologies Adverum Biotechnologies
ADVM
-131 M - - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
-26.2 M - 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
-48.1 M - -9.65 % $ 45.9 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
-38 M - - $ 7.46 M israelIsrael
Avenue Therapeutics Avenue Therapeutics
ATXI
-11.7 M - -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
-221 M $ 1.29 -3.01 % $ 329 M britainBritain
Stoke Therapeutics Stoke Therapeutics
STOK
-6.88 M $ 33.7 -0.27 % $ 2 B usaUSA
Atreca Atreca
BCEL
-97.2 M - -11.76 % $ 5.79 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
287 M - 0.49 % $ 251 B cayman-islandsCayman-islands
bluebird bio bluebird bio
BLUE
-212 M - - $ 546 M usaUSA
Heron Therapeutics Heron Therapeutics
HRTX
-20.2 M $ 0.83 3.62 % $ 138 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
84.9 M - -4.8 % $ 255 M usaUSA
Cara Therapeutics Cara Therapeutics
CARA
-119 M - -3.03 % $ 260 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
-132 M - - $ 3.74 B usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-155 M - - $ 1.01 B usaUSA
Avid Bioservices Avid Bioservices
CDMO
-141 M - - $ 789 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
-412 M - - $ 867 M germanyGermany
Savara Savara
SVRA
-119 M $ 5.25 -0.57 % $ 1.17 B usaUSA
China SXT Pharmaceuticals China SXT Pharmaceuticals
SXTC
-3.3 M $ 1.32 -5.2 % $ 1.88 M chinaChina
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
-19.8 M - -74.18 % $ 955 K usaUSA
Kala Pharmaceuticals Kala Pharmaceuticals
KALA
-38.5 M $ 0.2 -6.67 % $ 759 K usaUSA
Tarsus Pharmaceuticals Tarsus Pharmaceuticals
TARS
-66.4 M $ 67.2 0.36 % $ 2.81 B usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
-582 M $ 47.55 0.98 % $ 4.28 B schweizSchweiz
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
-33.5 M $ 4.45 -1.77 % $ 853 M canadaCanada
AIkido Pharma AIkido Pharma
AIKI
-14.7 M - 1.93 % $ 17.4 M usaUSA
Allakos Allakos
ALLK
-186 M - - $ 28.6 M usaUSA
Brickell Biotech Brickell Biotech
BBI
-5.69 M - -5.38 % $ 6.06 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
-48.7 M - 3.16 % $ 1.9 M usaUSA